Following the Gleevec Blueprint

March 20, 2013 | Blueprint Medicines has reunited the team behind Gleevec—Nick Lydon, Brian Druker, and Charles Sawyers. The startup, backed with a $40 million Series A financing from Third Rock Ventures and Fidelity Biosciences in 2011, believes now is the time for more drugs like the cancer blockbuster. They plan to use sequencing to identify genomic abnormalities that cause cancer, and then use the Gleevec model to target them. Xconomy